PTC Therapeutics | PTCT - Selling And Administration Expenses


PTC Therapeutics reported $73.89M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amgen USD 1.72B 134M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Cytokinetics USD 104.4M 499K Jun/2026
Daiichi Sankyo JPY 249.96B 21.73B Jun/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 1.52B 70M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026